3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
Key Takeaways
Chorionic villus sampling (CVS) obtains placental villi, typically at about 10–13 weeks; amniocentesis obtains amniotic fluid with fetal cells, typically from about 15–18+ weeks
Both procedures enable diagnostic chromosomal (karyotype/CMA) and molecular testing; choice hinges on timing needs, test menu, and counseling about placental vs fetal tissue
Modern procedure-related miscarriage risk estimates are lower than older historical figures often quoted as ~1% for CVS and ~0.5% for amniocentesis; counsel with current center/society estimates and operator experience
CVS can detect confined placental mosaicism; mosaic CVS results often lead to follow-up amniocentesis to clarify fetal status
Genetic counselors obtain informed consent covering purpose, alternatives (including declining), residual risk of missed diagnoses outside the assay, and result pathways—including uncertain/mosaic findings
3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
Quick Answer: CVS (≈10–13 weeks) biopsies chorionic villi (placenta); amniocentesis (≈15–18+ weeks) samples amniotic fluid with fetal cells. Both support diagnostic karyotype, CMA, and molecular assays. CVS mosaicism may be confined to placenta—often prompting amnio follow-up. Quote modern, lower procedure-related loss estimates rather than outdated one-size historical percentages, and always frame residual diagnostic limits.
Domain 3C tests whether you can choose the right procedure for gestational age and question, counsel mosaicism after CVS, and communicate risk without scare tactics or false precision.
Procedure Comparison
| Feature | CVS | Amniocentesis |
|---|---|---|
| Typical timing | ~10–13 weeks’ gestation | ~15–18+ weeks (earlier amnio historically associated with higher risk—avoid outdated early-amnio practices in counseling) |
| Sample | Chorionic villi (placental trophoblast/mesenchyme depending on processing) | Amniotic fluid (fetal cells shed into fluid; also AFP/AChE for ONTD in some protocols) |
| Earliest diagnostic answer | Earlier in pregnancy | Later than CVS |
| Key biologic caveat | Confined placental mosaicism; maternal cell contamination risk if not carefully processed | Generally better reflection of fetal genotype for chromosomal mosaicism questions; culture failure possible |
| Common test menu | Karyotype, CMA, targeted molecular testing, sometimes rapid aneuploidy tests | Same chromosomal/molecular menu; fluid AFP for open NTD assessment when indicated |
Transcervical vs transabdominal CVS and ultrasound-guided amniocentesis are technical routes chosen by the operator based on placenta location, gestation, and anatomy—counselors explain that approach is individualized.
What “Diagnostic” Still Does Not Mean
Even after CVS/amnio:
- The assay ordered must match the question (karyotype vs CMA vs single-gene test).
- Mosaic results require nuanced interpretation (true fetal mosaicism vs culture artifact vs CPM).
- Normal chromosomes do not exclude non-genetic disease or untested single-gene conditions.
- Maternal cell contamination can rarely confound molecular results—labs use identity markers when indicated.
Miscarriage and Complication Risk: Historical vs Modern Framing
Older teaching often quoted approximate excess miscarriage risks near 1% for CVS and 0.5% for amniocentesis. Contemporary evidence and society guidance generally support lower procedure-related loss rates in experienced centers—commonly discussed in ranges well under 1%, sometimes on the order of roughly 1 in several hundred to ~1 in 1,000, varying by study design, background loss rates, operator experience, and indication. Exact figures shift with literature updates; the exam-relevant skill is:
- Do not present historical round numbers as immutable universal truth.
- Distinguish background miscarriage risk at that gestation from attributable procedure risk.
- Note that risk is operator- and center-dependent.
- Include other complications in consent: bleeding, infection, membrane rupture, Rh sensitization (offer RhIG when indicated), and—for CVS—historical concerns about limb reduction with very early CVS (practice moved timing later to mitigate).
| Framing error | Better counseling |
|---|---|
| “CVS causes miscarriage 1% of the time in everyone” | “Older estimates were higher; current experienced-center risks are lower; your background risk also matters” |
| “Amnio is always twice as safe as CVS” | Compare timing needs, mosaicism issues, and local outcome data—not a slogan |
| Ignoring background loss | Many early losses occur with or without procedures |
Confined Placental Mosaicism After CVS
CPM = chromosomal mosaicism in the placenta with a different (often normal) fetal karyotype. Because CVS samples placenta, mosaic or aneuploid CVS results may not represent the fetus.
Counseling algorithm (conceptual):
- Explain that villi are placental tissue.
- Review whether mosaicism involves a chromosome associated with viable fetal mosaicism syndromes vs likely culture/CPM patterns (specialist interpretation).
- Offer amniocentesis for a fetal-cell-source karyotype/CMA when clarification is needed.
- Consider uniparental disomy (UPD) studies for certain chromosomes when mechanisms involve trisomy rescue (condition-specific—e.g., concerns for imprinted chromosomes).
- Coordinate detailed ultrasound and, if appropriate, postnatal confirmation plans.
Worked scenario. CVS karyotype shows mosaic trisomy 20. Amniocentesis is euploid and anatomy survey is normal. Counseling emphasizes likely CPM, residual low-level fetal mosaicism that cannot be entirely excluded, and postnatal pediatric awareness—without equating the CVS mosaic result to a definitive fetal diagnosis.
Contrast with NIPT: both NIPT and CVS are placenta-facing in different ways; amniocentesis is often preferred to resolve placenta–fetus discordance.
Choosing CVS vs Amniocentesis in Vignettes
| Clinical priority | Lean toward |
|---|---|
| Need earliest possible diagnostic genotype (e.g., known familial variant, early decision timeline) | CVS, if timing eligible and lab can run the assay on villi |
| Clarifying possible CPM / discordant NIPT / mosaic CVS | Amniocentesis |
| Concurrent ONTD biochemical assessment on fluid | Amniocentesis (AFP/AChE pathways) |
| Placenta inaccessible for CVS / contraindication | Amniocentesis at appropriate gestation |
| Patient declines all invasive testing | Respect; offer non-invasive screening and ultrasound pathway with clear residual-risk language |
Informed Consent Elements for GCs
Before referral or in co-counseling with MFM:
- Indication and expected yield
- Alternatives: no invasive test; screening only; waiting for postnatal testing
- Procedure steps in plain language
- Risk framing (modern estimates + uncertainty)
- Result timelines and possible uncertain/mosaic outcomes
- RhIG and infection precautions as applicable
- Psychosocial preparedness for results that may lead to continuation, specialized perinatal care, or pregnancy termination decisions
Exam trap: Presenting invasive testing as mandatory after any positive screen. The ethical and clinical standard is offer, with informed decline documented.
Master timing + tissue source + CPM follow-up + modern risk framing—those four pillars cover nearly all CVS/amnio board items.
A patient at 11 weeks wants the earliest diagnostic chromosomal testing after a high-risk NIPT. Which procedure timing/sample pairing is most appropriate to discuss first?
Amniocentesis at 11 weeks as first-line in all centers
Quad screen alone because it is diagnostic at 11 weeks
Routine delivery-cord karyotype only, with no prenatal diagnostic option
CVS at an appropriate 10–13 week window to sample chorionic villi for diagnostic testing, with counseling about placental mosaicism limitations
CVS shows mosaicism for a trisomy, and the patient wants to know whether the fetus is definitely affected. The most appropriate next counseling emphasis is:
Treat mosaic CVS as identical to fetal diagnosis in all cases and recommend immediate pregnancy termination without further testing
Explain possible confined placental mosaicism and discuss follow-up amniocentesis (and targeted additional studies when indicated) to better assess fetal status
State that mosaicism on CVS is always laboratory contamination and can be ignored
Switch only to maternal serum AFP, which resolves chromosomal mosaicism
How should genetic counselors frame procedure-related miscarriage risk for CVS and amniocentesis on contemporary exams?
Acknowledge that modern experienced-center estimates are generally lower than older historical figures (~1% CVS / ~0.5% amnio often taught historically), distinguish background loss from attributable risk, and avoid presenting outdated round numbers as universal constants
Always quote exactly 5% loss for both procedures regardless of center
Tell patients there is zero miscarriage risk if ultrasound guidance is used
Use only 1980s risk figures because they are more conservative and never mention newer data
Which statement best contrasts sample sources for prenatal diagnosis?
Both CVS and amniocentesis sample maternal lymphocytes exclusively
Amniocentesis samples chorionic villi; CVS samples amniotic fluid
CVS samples placental chorionic villi, whereas amniocentesis samples amniotic fluid containing fetal cells
Neither procedure can support chromosomal microarray when indicated
Sections you finish are checked off in the contents.